Lauren Buchanan, MA, Managing Editor

Earlier this summer, Meghan Heberton, MD, emphasized the importance and growth of the subspecialty.

At the conclusion of their roundtable event, Rocco Serrao, MD, FAAD; Latanya Benjamin, MD, FAAD; and Anthony Nuara, MD, PhD, discuss final considerations for tailoring vitiligo treatment plans.

Anthony Nuara, MD, PhD, reviewed a case study of a 32-year-old professional makeup artist who was concerned about her depigmented patches affecting her livelihood.

Latanya Benjamin, MD, FAAD, reviewed a case study of a 35-year-old woman with a 10-year history of vitiligo and concomitant atopic dermatitis

Explore recent research in in vitro complex skin models to study skin homeostasis, aging, and skin disease.

“This approval reflects our dedication to ensuring high-quality treatments are universally accessible,” Claire D’Abreu-Hayling, chief scientific officer of Sandoz, said in a news release.

Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.

Rocco Serrao, MD, FAAD, reviewed a case study of a 20-year-old man with segmental vitiligo and the psychological impact of his vitiligo.

A recent study reviewed the current evidence on the impact of key vitamins and minerals on rosacea and provided clinical recommendations.

A growing body of research is dedicated to understanding how various climatic elements impact AD.

Explore the disease progression of atopic dermatitis and strategies to make a difference in patients' lives.

The investigator in the clinical development program for deuruxolitinib shared data, patient populations to consider, and more in a recent interview.

The study focused on the use of Internet resources, number of medical consultations, and factors influencing treatment outcomes.

Take a deep dive into the 3 approvals for various dermatological conditions this month.

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

Investigators looked into pollutant-induced disruption of the skin barrier, increased transepidermal water loss, and heightened inflammatory responses.

Along with the approval, Sun Pharma is introducing an access program to assist eligible patients in starting and adhering to the treatment.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how the publication has impacted their practice.

The submission to the FDA is supported by positive results from the ARRECTOR phase 3 trial.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on key career mentors.

Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab.

Robert Posnick, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving hyperpigmentation and alopecia areata.

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how patient interactions have changed over time.

Ben Lockshin, MD, FAAD, shared his insights on the latest advancements in oral options for psoriasis therapies.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Mona Shahriari, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis in patients with skin of color.

Jenny Murase, MD, and Elizabeth Kiracofe, MD, highlighted key clinical considerations to optimize atopic dermatitis care for patients during pregnancy, prepregnancy, postpartum, and breastfeeding.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on advancements in their careers.

Learn more about the latest research in atopic dermatitis from Raj Chovatiya, MD, PhD, MSCI; Robert Sidbury, MD; David Rosmarin, MD; Amy Paller, MD; Melinda Gooderham, MD, MSc, FRCPC; and Jonathan Silverberg, MD, PhD, MPH.